Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

One NASDAQ - Listed Energy Stock Under Radar - UROY

May 27, 2025 | Team Kalkine
One NASDAQ - Listed Energy Stock Under Radar - UROY
Image source: shutterstock

  • UROY:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Uranium Royalty Corp

Uranium Royalty Corp (NASDAQ: UROY) is a company dedicated to the uranium sector, aiming to benefit from movements in uranium prices by strategically investing in various uranium-related assets. These include royalties, streaming agreements, equity and debt positions in uranium companies, as well as direct ownership of physical uranium. Its diverse portfolio features assets such as Anderson, Church Rock, Cigar Lake/Waterbury Lake, Dawn Lake, Dewey-Burdock, Energy Queen, Lance, Langer Heinrich, McArthur River, Michelin, Reno Creek, among others.

Financial Updates:

  • Strategic Arrangement with Yellow Cake plc: UROY holds an option, through a strategic agreement with Yellow Cake plc, to acquire up to USUSD 21.25 million worth of uranium (U₃O₈) by January 2025, sourced via Yellow Cake’s arrangement with Kazatomprom. Though UROY last exercised this option in fiscal 2021, the agreement also includes rights to co-invest in royalty and streaming opportunities identified by Yellow Cake and to collaborate on physical uranium acquisitions. The war in Ukraine introduces geopolitical uncertainty, potentially disrupting uranium logistics from Kazakhstan, but could also favor North American uranium demand and pricing.
  • Overall Performance: UROY reported a net loss of USD 1.9 million for Q3 FY2025 and USD 4.5 million for the nine months ended January 31, 2025, a reversal from net income in the comparable periods of FY2024. Despite this, the Company maintained a strong working capital position of USD 238.2 million, with its performance affected by market trends in uranium, nuclear energy demand, and geopolitical events.
  • Discussion of Operations: The Q3 FY2025 net loss was mainly due to the absence of uranium sales, unlike the previous year when sales generated USD 5.7 million in gross profit. Office and admin costs rose, largely from increased marketing and storage fees tied to higher inventory levels. Foreign exchange losses and tax expenses were lower than the prior year. For the nine-month period, losses were similarly attributed to reduced uranium sales, higher admin expenses, and finance costs from an extinguished inventory financing arrangement.
  • Summary of Quarterly Results: UROY’s financial results have varied quarter to quarter, primarily driven by uranium sales activity and market-driven changes in the fair value of investments. Net income was positive in several quarters of FY2024 and early FY2025 but turned negative in later periods due to limited uranium sales and lower investment gains.
  • Liquidity and Capital Resources: UROY's liquidity remains strong, with USD 238.2 million in working capital as of January 31, 2025. Cash decreased due to uranium acquisitions and operations but was partially offset by USD 26 million in proceeds from exercised warrants and options. Inventory levels increased significantly due to purchases and in-kind royalty receipts. The Company is financially positioned to meet upcoming commitments, including a USD 7.1 million uranium purchase in April 2025, and it recently secured a U₃O₈ sale agreement generating USD 3.2 million.

Technical Observation (on the daily chart):

UROY has surged 19.5% to USD 2.33, breaking above its 21-day (USD 1.92) and 50-day (USD 1.83) moving averages with strong volume, signaling a bullish trend reversal after months of decline. The RSI at 74 indicates overbought conditions, suggesting a possible short-term pullback or consolidation despite strong momentum.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to Uranium Royalty Corp (NASDAQ: UROY) at the closing market price of USD 2.33 as of May 23,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 23,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.


Disclaimer-

Disclaimer This report has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine). Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.

Past performance is not a reliable indicator of future performance.